309 publications
Name | Date | Type | Actions |
---|---|---|---|
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
29/04/2024 | Public releases | |
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
BALO : Notice of meeting Shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 28, 2024 at 11 a.m. at the Company's registered office, Magny-Vernois 70 200 LURE, in order to deliberate on the following agenda and draft resolutions |
22/04/2024 | Shareholders´s Meeting | |
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
20/03/2024 | Public releases | |
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
24/01/2024 | Public releases | |
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
26/10/2023 | Public releases | |
Rapport financier semestriel 2023 (french) Rapport financier semestriel 2023 (french) |
12/09/2023 | Half Year Report | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
2023 Half-Year Results Contents |
07/09/2023 | Half Year Report | |
Rapport financier semestriel 2022 (french) Rapport financier semestriel 2022 (french) |
26/06/2023 | Half Year Report | |
Rémunération et politique des dirigeants - mai 2023 (french) Rémunération et politique des dirigeants |
07/06/2023 | Shareholders´s Meeting | |
Vetoquinol - assemblée générale mixte - 25 mai 2023 : résultat du scrutin |
26/05/2023 | Shareholders´s Meeting | |
Assemblée générale - Vetoquinol SA 25 mai 2023 Ordre du jour : |
25/05/2023 | Shareholders´s Meeting | |
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – record date Conformément aux dispositions des articles L233-8-II du Code de Commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers |
24/05/2023 | Shareholders´s Meeting | |
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
20/04/2023 | Public releases | |
BALO : Avis de convocation / avis de réunion Mesdames et Messieurs les actionnaires sont convoqués le jeudi 25 mai 2023 à 11h00 au siège social, Magny-Vernois 70200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions ci-après. |
14/04/2023 | Shareholders´s Meeting | |
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
13/04/2023 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
First nine months 2022 sales: €405M In line with year-end outlook |
12/10/2022 | Public releases | |
2022 HALF YEAR RESULTS Additional information on the Group’s strategy Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook. |
23/09/2022 | Public releases , Half Year Report | |
2022 half-year results This document has been prepared by Vetoquinol for the sole purpose of presenting the half-year results for the fiscal year 2022, on September 15, 2022. |
15/09/2022 | Half Year Report | |
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
15/09/2022 | Public releases | |
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
20/07/2022 | Public releases | |
Remuneration vote results - AG may 2022 |
20/05/2022 | Shareholders´s Meeting | |
Vote results - AG may 19, 2022 |
20/05/2022 | Shareholders´s Meeting | |
Information regarding the total number of voting rights and shares making of the share capital - 12 may 2022 As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers» |
13/05/2022 | Shareholders´s Meeting | |
Balo new information Balo new information |
05/05/2022 | Shareholders´s Meeting | |
Number of voting rights and shares making of the share capital Information regarding the total number of voting rights and shares making of the share capital - J-21 before AGM as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers » |
03/05/2022 | Shareholders´s Meeting | |
Annual general meeting 2022 - brochure |
28/04/2022 | Shareholders´s Meeting | |
Availability of the 2021 universal registration document Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022. |
22/04/2022 | Public releases | |
Vote by post / proxy form Vote by post of proxy form for annual general meeting on May 19, 2022 |
19/04/2022 | Shareholders´s Meeting | |
General annual meeting - may 19 2022 Annual General Meeting on May 19, 2022 - convocation |
19/04/2022 | Shareholders´s Meeting | |
Q1 2022 SALES: €135M Q1 2022 SALES: €135M |
13/04/2022 | Public releases | |
2021 Annual results ALL FINANCIAL INDICATORS UP. |
24/03/2022 | Public releases | |
Double-digit growth in 2021 Total Group Sales: €521 million (up 21.9% as reported) |
20/01/2022 | Public releases | |
Third quarter revenues: €132 million |
14/10/2021 | Public releases | |
[Video] Présentation des résultats semestriels 2022 - french Présentation analystes & investisseurs - 15 septembre 2022 |
29/07/2021 | Half Year Report | |
[VIDEO] Présentation des résultats semestriels 2021 - french Présentation analystes & investisseurs - 29 juillet 2021 |
29/07/2021 | Half Year Report | |
H1 2021 results H1 2021 results |
29/07/2021 | Half Year Report | |
2021 Half year Financial Report (french) Half year Financial Report (french version) |
29/07/2021 | Half Year Report | |
2021 first half results 2021 Half year results |
29/07/2021 | Public releases | |
Rémunération et politique des dirigeants (french) Résultats des votes de l’Assemblée Générale Mixte du 27 mai 2021 |
28/05/2021 | Shareholders´s Meeting | |
Résultats du scrutin de l'Assemblée Générale mixte du 26 mai 2020 (french) Résultats du scrutin |
28/05/2021 | Shareholders´s Meeting | |
Assemblée générale mixte du 27 mai 2021 (french) Présentation de l'Assemblée Générale annuelle mixte du 27 mai 2021 |
27/05/2021 | Shareholders´s Meeting | |
Formulaire de vote 2021 (french) Assemblée Générale Mixte du 27 mai 2021 |
04/05/2021 | Shareholders´s Meeting | |
Avis de réunion valant avis de convocation (french) Mesdames et Messieurs les actionnaires sont convoqués le jeudi 27 mai 2021 à 14h00, au siège social, Magny-Vernois 70 200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions ci-après. Cette Assemblée se tiendra dans le strict respect des gestes barrières.
|
04/05/2021 | Shareholders´s Meeting | |
Availability of the 2020 universal registration document Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021. |
28/04/2021 | Public releases | |
Avis de réunion valant avis de convocation (french) Mesdames et Messieurs les actionnaires sont convoqués le jeudi 27 mai 2021 à 14h00, au siège social, Magny-Vernois 70 200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants : |
28/04/2021 | Shareholders´s Meeting | |
Q1 2021 sales Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)
|
15/04/2021 | Public releases | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
Vetoquinol wins the Animal Pharm’s award for best European company 2020 February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. |
08/02/2021 | Public releases | |
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
08/02/2021 | press release excluding results | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases | |
Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements. |
18/01/2021 | Public releases | |
Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health. |
11/01/2021 | Public releases | |
Q3 2020 sales: €114.5 million* (Up 14.3%) Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year. |
15/10/2020 | Public releases | |
VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare. |
28/09/2020 | Public releases | |
Vetimpress delivering digital solutions to farm vets with a growing network of partnerships September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions. |
21/09/2020 | Public releases | |
Vetoquinol finalizes the acquisition of Profender® and Drontal® product families September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020. |
02/09/2020 | Public releases | |
2020 Half year Financial Report (french) Half year Financial Report |
31/07/2020 | Half Year Report | |
[VIDEO] Présentation des résultats semestriels 2020 - french |
31/07/2020 | Half Year Report | |
H1 2020 results H1 2020 Result
|
30/07/2020 | Half Year Report | |
2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales) At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
30/07/2020 | Public releases | |
Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health. |
09/06/2020 | Public releases | |
Rémunération et politique des dirigeants (french) Résultats des votes de l’Assemblée Générale Mixte du 26 mai 2020 |
29/05/2020 | Shareholders´s Meeting | |
Combined Ordinary and Extraordinary General Meeting of May 26, 2020 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 26, 2020 in Lure, chaired by Etienne Frechin. The shareholders did not physically attend this meeting in view of the restrictions on gatherings due to the health crisis in France. |
27/05/2020 | Shareholders´s Meeting | |
Résultats du scrutin de l'Assemblée Générale mixte du 26 mai 2020 (french) Résultats du scrutin |
27/05/2020 | Shareholders´s Meeting | |
Assemblée Générale Annuelle Mixte (french) 26 mai 2020 |
26/05/2020 | Shareholders´s Meeting | |
Brochure Vetoquinol AGM en huis clos Mesdames et Messieurs les actionnaires,
Le conseil d’administration a décidé de faire usage des dispositions de l’ordonnance n°2020-321 du 25 mars 2020 portant adaptation des règles de réunion et de délibération des assemblées et organes dirigeants des personnes morales et entités dépourvues de personnalité morale de droit privé en raison de la crise sanitaire actuelle et des restrictions de déplacement et réunion qu’elle impose. En conséquence, l’assemblée générale mixte de VETOQUINOL SA se tiendra le mardi 26 mai 2020 à 14h45, au siège social, Magny-Vernois 70 200 LURE, à huis clos, sans que les actionnaires et les autres personnes ayant le droit d’y assister ne soient présents physiquement.
|
07/05/2020 | Shareholders´s Meeting | |
Dominique Derveaux appointed Group Chief Operations Officer
Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin. |
28/04/2020 | Public releases | |
Availability of the 2019 universal registration document Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020. |
23/04/2020 | Public releases | |
Q1 2020 sales €103.4 million (Up 13.7%) Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates. |
16/04/2020 | Public releases | |
Formulaire de vote Formulaire de vote - Assemblée générale mixte - 26 mai 2020 - siège social Magny-Vernois 70200 LURE |
16/04/2020 | Shareholders´s Meeting | |
Avis de réunion valant avis de convocation (french) Mesdames et Messieurs les actionnaires sont convoqués le mardi 26 mai 2020 à 14h45, au siège social, Magny-Vernois 70 200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants : |
16/04/2020 | Shareholders´s Meeting | |
2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales) At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
26/03/2020 | Public releases | |
Covid-19: Vetoquinol donates masks to neighboring healthcare facilities Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions. |
20/03/2020 | Public releases | |
Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health. |
12/02/2020 | Public releases | |
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
23/01/2020 | Public releases | |
Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. |
13/12/2019 | Public releases | |
Q3 2019 sales: €100.2 million (Up 11.0%) The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. |
16/10/2019 | Public releases | |
[AUDIO] Présentation des résultats semestriels 2019 - french Vetoquinol - 25.07.2019 - Enregistrement Audio Conference |
26/07/2019 | Half Year Report | |
2019 Half year Financial Report (french) Half year Financial Report |
25/07/2019 | Half Year Report | |
H1 2019 RESULTS H1 2019 results
|
25/07/2019 | Half Year Report | |
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
25/07/2019 | Public releases | |
Vetoquinol announces a new milestone in its industrial strategy Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners. |
12/07/2019 | Public releases | |
Monthly information regarding the total number of voting rights and shares making of the share capital - June 2019 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
03/07/2019 | Shareholders´s Meeting | |
Monthly information regarding the total number of voting rights and shares making of the share capital - May 2019 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
06/06/2019 | Shareholders´s Meeting | |
Combined ordinary and extraordinary general meeting May 21, 2019 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin. |
22/05/2019 | Public releases | |
Résultats du scrutin de l'Assemblée générale du 24 mai 2016 (french) Assemblée générale mixte du 24 mai 2016 |
22/05/2019 | Shareholders´s Meeting | |
Assemblée Générale Annuelle Mixte 21 mai 2019 |
21/05/2019 | Shareholders´s Meeting | |
Monthly information regarding the total number of voting rights and shares making of the share capital - March 2019 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
30/04/2019 | Shareholders´s Meeting | |
Avis de réunion valant avis de convocation (french) Mesdames et Messieurs les actionnaires sont convoqués le mardi 30 mai 2017 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants : |
30/04/2019 | Shareholders´s Meeting | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version) The registration document of Vetoquinol relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers (“the AMF”) on April 29, 2019.
|
29/04/2019 | Public releases | |
Q1 2019 sales: €90.9 million (up 3.7%) Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year. |
17/04/2019 | Public releases | |
Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
|
16/04/2019 | Public releases | |
Formulaire de vote |
15/04/2019 | Shareholders´s Meeting | |
Avis de réunion valant avis de convocation (french) Mesdames et Messieurs les actionnaires sont convoqués le mardi 30 mai 2017 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants : |
15/04/2019 | Shareholders´s Meeting | |
Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás. |
04/04/2019 | Public releases | |
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
20/03/2019 | Public releases |